Canada & Merck Group

Canada: Authorized Moderna's vaccine trial and restricted travel from DRC, contributing to global response.

Merck Group: Merck Group's Ervebo vaccine is being deployed in the outbreak response, potentially increasing sales. However, its efficacy against the Bundibugyo strain is unproven, and the trial outcome will be critical.

Canada: Approved Moderna's vaccine trial and imposed entry restrictions on travelers from DRC. Its regulatory support is important for vaccine development.

Merck Group: Manufacturer of RVSV-ZEBOV vaccine, which is being considered for cross-protection trials. Its vaccine could play a role in the response, benefiting its reputation.

Canada: Canada is a potential market, with melanoma incidence and patient advocacy groups responding positively.

Merck Group: Merck co-developed the vaccine and provided Pembrolizumab, the combination partner. Its shares rose about 10-12%, and the success helps Merck prepare for Pembrolizumab's patent expiration by expanding its cancer portfolio.

Canada: Similarly uses combination MMR, highlighting inconsistency in the administration's claims.

Merck Group: As a major MMR manufacturer, it faces potential regulatory and market changes. It stated no scientific evidence supports splitting the vaccine, and it may face pressure to develop separate shots.